Vera Therapeutics (VERA) Times Interest Earned (2020 - 2026)
Vera Therapeutics' (VERA) quarterly Times Interest Earned came in at -$0.74 in Q1 2026, up 84.96% YoY from -$0.4 in Q1 2025, and up 56.01% on a QoQ basis from -$1.68 in Q4 2025.
Powered by 
Analysis
Vera Therapeutics (VERA) Times Interest Earned (2020 - 2026) Analysis & Trends
Vera Therapeutics (VERA) has 7 years of Times Interest Earned data on file, last reported at -$0.74 in Q1 2026.
- Quarterly Times Interest Earned rose 84.96% year-over-year to -$0.74 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.26 (up 60.44% YoY) and the FY2025 annual result came in at -$1.21, down 24.96% from the prior year.
- Times Interest Earned grew to -$0.74 in Q1 2026, from -$1.68 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$0.74 in Q1 2026 to a low of -$60.07 in Q4 2022.
- A 5-year average of -$13.37 and a median of -$4.73 in 2024 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2022 — Times Interest Earned tumbled 1252.35% — and 2023, when it jumped 96.67%.
- Tracing VERA's Times Interest Earned over 5 years: stood at -$60.07 in 2022, then jumped by 96.67% to -$2.0 in 2023, then tumbled by 1205.13% to -$26.14 in 2024, then jumped by 93.58% to -$1.68 in 2025, then jumped by 56.01% to -$0.74 in 2026.
- The last three Times Interest Earned figures came in at -$0.74 (Q1 2026), -$1.68 (Q4 2025), and -$26.03 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Vera Therapeutics | 2.58 Bn | 2.58 Bn | - | -60.87 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -60.87 |
| Mar 31, 2026 | -68.64 |
| Dec 31, 2025 | -49.48 |
| Sep 30, 2025 | -42.82 |
| Jun 30, 2025 | -42.76 |
| Mar 31, 2025 | -31.92 |
| Dec 31, 2024 | -26.14 |
| Sep 30, 2024 | -25.72 |
| Jun 30, 2024 | -19.53 |
| Mar 31, 2024 | -16.32 |
| Dec 31, 2023 | -25.59 |
| Sep 30, 2023 | -23.07 |
| Jun 30, 2023 | -24.04 |
| Mar 31, 2023 | -35.76 |
| Dec 31, 2022 | -56.06 |
| Sep 30, 2022 | -171.73 |
| Jun 30, 2022 | -117.63 |
| Mar 31, 2022 | -144.25 |
| Dec 31, 2021 | -829.25 |
| Dec 31, 2020 | -2,837.33 |